Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Liposomal bupivacaine TAP block for post-cesarean analgesia
ChiCTR2500103390Phase 4Recruiting
- Sponsor
- Meishan maternal and child care service center
- Start
- May 2025
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of liposomal bupivacaine, morphine and nalbuphine in postoperative pain (3 arms), sponsored by Meishan maternal and child care service center. Primary endpoint: Total opioid consumption at 72 hours. Started May 2025; status: recruiting.
02
Drugs
liposomal bupivacainemorphinenalbuphine
03
Conditions
postoperative pain
Beyond the preview
Go deeper on ChiCTR2500103390.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500103390.